Quintrio
Home

SURGICAL & MEDICAL INSTRUMENTS & APPARATUS

GLOBUS MEDICAL INC

GMED

Through innovative technology and M&A activity, Globus Medical transformed into the number two medical device manufacturer in the competitive spine market. The firm was founded in 2003 with a heavy focus on internal research and development but vaulted its market share in 2023 through a merger with former competitor NuVasive. In 2025, the company acquired Nevro, a smaller player that specialized in spinal cord stimulation therapy. Globus Medical reports two business segments, musculoskeletal solutions and enabling technologies, which consist of implants used in surgery and associated technologies that assist the physician.

Last trade $70.28
Day change -$0.22 (-0.31%)
Day range $69.54 – $72.51
Volume 503,858
Market cap $9.34B

Open XNYS

Fundamentals

Key company ratios and reported financial statements.

Source: Massive.com

Key ratios

Valuation

Market capitalization
$9.34B
Price / earnings
16.75×
Price / book
1.95×
Price / sales
2.97×
EV / sales
2.83×
EV / EBITDA
8.94×

Profitability

Earnings per share
$4.21
Return on assets
10.09%
Return on equity
11.63%
Dividend yield
0%

Liquidity and leverage

Debt / equity
0×
Current ratio
3.88×
Quick ratio
2.41×
Cash ratio
0.78×

Cash flow

Price / cash flow
10.09×
Price / free cash flow
12.18×
Free cash flow
$766.55M

Ratios use trailing-twelve-month financials and market data as of Nov 16, 2026.

Financial statements

Income and cash flow amounts are for the period; balance sheets are point-in-time snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are displayed when available.

Income statement for GMED, quarterly periods
Line itemQ3 FY2026 Sep 30, 2026Q2 FY2026 Jun 30, 2026Q1 FY2026 Mar 31, 2026Q4 FY2025 Dec 31, 2025Q3 FY2025 Sep 30, 2025Q2 FY2025 Jun 30, 2025Q1 FY2025 Mar 31, 2025Q4 FY2024 Dec 31, 2024
Revenue$763.72M$789.61M$759.85M$826.42M$769.05M$745.34M$598.12M$657.29M
Cost of revenue$232.92M$241.44M$234.07M$261.11M$252.53M$248.77M$195.4M$263.44M
Gross profit$530.8M$548.17M$525.79M$565.31M$516.52M$496.58M$402.72M$393.86M
Selling, general and administrative$288.47M$286.82M$297.78M$318.48M$313.6M$303.62M$242.8M$253.17M
Research and development$34.53M$36.32M$36.51M$36.16M$38.07M$39.95M$33.06M$33.41M
Total operating expenses$353.25M$365.74M$375.4M$395.97M$379.15M$420.47M$305.72M$333.58M
Operating income$177.55M$182.43M$150.39M$169.34M$137.36M$76.11M$97M$60.27M
Interest expense$8.41M$7.07M$5.43M-$3.83M$1.46M$693K$1.68M$5M
Income before taxes$183.27M$189.82M$157.07M$169.23M$143.99M$188.17M$103.67M$24.67M
Income taxes$42.1M$38.25M$32.77M$28.64M$25.03M-$14.67M$28.21M-$1.84M
Net income$141.17M$151.57M$124.3M$140.59M$118.97M$202.85M$75.46M$26.51M
Net income attributable to common shareholders$141.17M$151.57M$124.3M$140.59M$118.97M$202.85M$75.46M$26.51M
EBITDA$248.6M$264.97M$231.83M$250.32M$225.71M$193.44M$163.71M$144.96M
Basic earnings per share$1.05$1.12$0.92$1.05$0.88$1.50$0.55$0.19
Diluted earnings per share$1.04$1.10$0.90$1.03$0.88$1.49$0.54$0.19

Recent news

Company coverage with links to the original publishers.

Publication times in UTC
Zacks Investment Research

Should You Continue to Hold ALGN Stock in Your Portfolio?

Align Technology has gained 25.4% over the past year, outperforming the S&P 500, driven by Invisalign portfolio expansion into younger patients and complex cases, plus strategic DSO partnerships. However, the stock faces headwinds from currency volatility and intense competition from traditional braces and lower-priced clear aligner alternatives. The company holds a Zacks Rank #3 (Hold) with 2026 EPS estimates revised down 1.5% to $11.12.

Zacks Investment Research

Here's Why You Should Retain NVST Stock in Your Portfolio for Now

Envista Holdings (NVST) has gained 24% over the past year, outperforming its industry, driven by international expansion, new product launches, and strong earnings beats. The company achieved 9% adjusted EBITDA growth and 25% EPS growth. However, fierce competition, weakness in China sales, and foreign exchange headwinds pose risks to future revenue and margin expansion.

Zacks Investment Research

Should You Continue to Retain Bruker Stock in Your Portfolio?

Bruker Corporation (BRKR) is well-positioned for growth driven by strong diagnostics and biosystems revenue, favorable European demand, and a $140 million cost-savings target by 2026 aimed at expanding margins by 250-300 basis points. However, uneven U.S. academic demand, macroeconomic uncertainty, and trade policy volatility present headwinds. The stock carries a Zacks Rank #3 (Hold) rating with a 3.4% earnings yield.

Zacks Investment Research

Hims & Hers Q3 Earnings Miss Estimates, Gross Margin Down

Hims & Hers (HIMS) reported Q3 2026 EPS of 3 cents, missing estimates by 57.1%, though revenues grew 48.7% year-over-year to $890.4 million. The company faced margin compression due to lower-margin weight loss products and a sequential subscriber decline of 100,000. HIMS lowered its full-year adjusted EBITDA guidance to $257-$277 million but raised international revenue outlook to at least $650 million.

Zacks Investment Research

Rigetti Q3 Earnings In Line With Estimates, Revenues Down Y/Y

Rigetti Computing (RGTI) reported Q2 2026 adjusted loss per share of 6 cents with revenues declining 27.5% to $1.41 million, missing consensus estimates by 57.6%. Despite gross margin expansion to 60.7%, operating losses widened to $33.19 million due to increased R&D spending. The company targets $20 million in 2026 revenues and plans to develop a 300+ qubit quantum system by mid-2028.

Dividends

Declared distributions and recorded event dates. Forecasts are not shown.

Updated daily

No declared upcoming dividend found.

No prior dividend records found.

Stock splits

Historical share-structure events and their execution dates.

Updated daily

No stock split records found.